References
- Chapman PB , HauschildA, RobertC et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26) , 2507–2516 (2011).
- Flaherty KT , PuzanovI, KimKB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9) , 809–819 (2010).
- Kefford R , ArkenauH, BrownMP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Presented at: 2010 ASCO Annual Meeting: Clinical Science Symposium, Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets. Chicago, IL, USA, 4–8 June 2010 (Abstract 8503).
- Ribas A , KimKB, SchuchterLM et al. BRIM-2: an open-label, multicenter Phase II study of vemurafenib inpreviously treated patients with BRAF V600E mutation-positive metastatic melanoma. Presented at: 2011 ASCO Annual Meeting: Oral Abstract Session, Melanoma/Skin Cancers. Chicago, IL, USA, 4–8 June 2010 (Abstract 8509).
- Tiacci E , TrifonovV, SchiavoniG et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med.364(24) , 2305–2315 (2011).
- Nazarian R , ShiH, WangQ et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326) , 973–977 (2010).
- Poulikakos PI , PersaudY, JanakiramanM et al. Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF (V600E) that dimerize in a RAS independent manner. Nature doi:10.1038/nature10662 (2011) (Epub ahead of print).
- Villanueva J , VulturA, LeeJT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6) , 683–695 (2010).
- Shi H , KongX, RibasA, LoRS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to B-RAF(V600E) inhibition. Cancer Res.71(15) , 5067–5074 (2011).
- Sequist LV , WaltmanBA, Dias-SantagataD et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75) , 75ra26 (2011).
- Su F , VirosA, MilagreC et al. RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. N. Engl. J. Med. doi: 10.1200/JCO.2011.36.7680 (2011) (Epub ahead of print).
- Infante JR , FalchookGS, LawrenceDP et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Presented at: 2011 ASCO Annual Meeting: Clinical Science Symposium, BRAF: From Biology to Patients. Chicago, IL, USA, 4–8 June 2010 (Abstract CRA8503).
- Pleasance ED , CheethamRK, StephensPJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278) , 191–196 (2010).
- Durinck S , HoC, WangNJ et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 1(2) , 137–143 (2011).
- Sathirapongsasuti JF , LeeH, HorstBA et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: exome CNV. Bioinformatics 27(19) , 2648–2654 (2011).